<?xml version="1.0" encoding="UTF-8"?>
<p>
 <italic>Remdesivir</italic> is an RNA‐dependent RNA polymerase inhibitor that is active against a wide range of RNA viruses. It was originally developed for the treatment of Ebola virus infection and shows good activity against COVID‐19 in vitro. Foreign and domestic clinical reports show its possible clinical importance, but an RCT of remdesivir was discontinued in China.
 <xref rid="jog14384-bib-0044" ref-type="ref">
  <sup>44</sup>
 </xref> Although remdesivir may be effective against COVID‐19, serious side effects, including severe liver dysfunction, diarrhea, skin rash and renal dysfunction, are frequent.
</p>
